Aasems Jacob

Aasems Jacob

University of Kentucky

H-index: 8

North America-United States

About Aasems Jacob

Aasems Jacob, With an exceptional h-index of 8 and a recent h-index of 8 (since 2020), a distinguished researcher at University of Kentucky, specializes in the field of Oncology, Hematology, Healthcare disparities, Immunotherapy, Lung Cancer.

His recent articles reflect a diverse array of research interests and contributions to the field:

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib

A Tale of Two Hematological Malignancies: CML Followed by CLL in the Same Patient

Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs

AIMS65, Glasgow-Blatchford bleeding score and modified Glasgow-Blatchford bleeding score in predicting outcomes of upper gastrointestinal bleeding: An accuracy and calibration …

Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment

Epidemiology and determinants of survival for primary intestinal non-Hodgkin lymphoma: a population-based study

A Case of Undiagnosed Functional Gonadotroph Adenoma Leading to Ovarian Hyperstimulation Syndrome

Oxalate Nephropathy in a Patient with COVID-19-Infection: Causation or Association

Aasems Jacob Information

University

University of Kentucky

Position

___

Citations(all)

238

Citations(since 2020)

220

Cited By

63

hIndex(all)

8

hIndex(since 2020)

8

i10Index(all)

8

i10Index(since 2020)

6

Email

University Profile Page

University of Kentucky

Aasems Jacob Skills & Research Interests

Oncology

Hematology

Healthcare disparities

Immunotherapy

Lung Cancer

Top articles of Aasems Jacob

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib

Authors

Anna E Johnson,Athul Raj Raju,Aasems Jacob,Gerhard C Hildebrandt

Journal

Frontiers in Oncology

Published Date

2023/1/12

Hairy cell leukemia (HCL) is a rare mature B-cell lymphoproliferative disorder and most often presents as classic hairy cell leukemia. This entity is characterized by an indolent course and the presence of the BRAF V600E mutation. We report the case of an 80-year-old man with a history of classical hairy cell leukemia who presented with fatigue, dizziness, shortness of breath, blurring of vision, and headache. His initial diagnosis was 9 years prior, and he received treatments with cladribine, pentostatin, and rituximab. The workup showed an elevated white blood cell count with atypical lymphocytes, anemia, and thrombocytopenia. A peripheral blood smear confirmed HCL relapse, and a magnetic resonance imaging (MRI) of the brain showed diffuse, nonenhancing masses in the supratentorial and infratentorial regions of the brain. He was initiated on treatment with vemurafenib, with improvements in his white blood cell count and a recovery of his platelet count and hemoglobin. A repeat MRI of the brain after 3 months showed complete resolution of the lesions. Vemurafenib was discontinued after 6 months, with bone marrow biopsy showing no evidence of residual hairy cell leukemia. There have only been limited reports of HCL involvement in the central nervous system in the literature. Due to the rarity of the condition, it is not clear which treatments can be effective for intracranial disease control. Our report shows the successful use of vemurafenib, resulting in complete remission of relapsed HCL with CNS involvement.

A Tale of Two Hematological Malignancies: CML Followed by CLL in the Same Patient

Authors

Insija Selene,Aasems Jacob,Zain Mary El-Amir,Sanjivani Sathe,Asma Taj

Journal

Annals of Internal Medicine: Clinical Cases

Published Date

2023/1/3

Studies have reported second malignancies occurring in patients with chronic myeloid leukemia (CML) or chronic lymphoid leukemia (CLL). We discuss the case of a 77-year-old man diagnosed with CLL who later developed CML. The CLL was managed with surveillance after diagnosis for 3 years and later treated with ibrutinib and venetoclax. While on treatment with venetoclax for 4 months, the patient had worsening leukocytosis shown via peripheral flow cytometry and fluorescence in situ hybridization, with the presence of myeloid lineage cells positive for BCR-ABL and complete disappearance of lymphoid cells. This case report highlights the importance of considering a second malignancy in hematologic malignancies with variable disease prognosis.

Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs

Authors

Zhonglin Hao,Saurabh Parasramka,Quan Chen,Aasems Jacob,Bin Huang,Timothy Mullett,Al B Benson

Journal

The Oncologist

Published Date

2023/1/1

Background Overall survival advantage of chemotherapy before versus after metastasectomy of liver or lung lesion is not clear for colon cancer with synchronous liver or lung metastasis. Materials and Methods Adults 20 years or older with primary colon cancer and single organ metastatic disease either in the liver or lung at diagnosis were identified between 2010 and 2015 through the National Cancer Database (NCDB). Patients were categorized into 2 cohorts: pre-operative/peri-operative chemotherapy (neoadjuvant –[NAC]) or post-operative chemotherapy (adjuvant [AC]). Survivals and factors associated with were compared between the 2 groups. Results A total of 3038 patients with colon cancer with liver or lung metastases were identified. The percentage of patients receiving NAC had steadily increased from 12.29% to 28.31%, mostly in academic …

AIMS65, Glasgow-Blatchford bleeding score and modified Glasgow-Blatchford bleeding score in predicting outcomes of upper gastrointestinal bleeding: An accuracy and calibration …

Authors

PV Akhila Arya,NK Thulaseedharan,Rishi Raj,Dileep C Unnikrishnan,Aasems Jacob

Journal

Indian Journal of Gastroenterology

Published Date

2023/8

BackgroundAlbumin, international normalized ratio (INR), mental status, systolic blood pressure, age >65 years (AIMS65), Glasgow-Blatchford bleeding score (GBS) and modified GBS (mGBS) are three pre-endoscopy scoring systems used in the risk stratification of upper gastrointestinal bleeding (UGIB). The utility of such scoring systems in a population is estimated by their accuracy and calibration in the population. We aimed at validating and comparing the accuracy of the three scoring systems in predicting clinical outcomes including in-hospital mortality, need for blood transfusion, endoscopic treatment and rebleeding risk.MethodWe conducted a single-center, retrospective cohort study on patients with UGIB at a tertiary care center in India over 12 months. Clinical and laboratory data was collected from all patients admitted with UGIB. All patients were risk stratified using AIMS65, GBS and mGBS. The clinical …

Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment

Authors

Ghada Elshimy,Rishi Raj,Aasems Jacob,Ricardo Correa

Journal

BMJ Case Reports CP

Published Date

2022/3/1

Pituitary apoplexy (PA) is a clinical condition characterised by a sudden increase in pituitary gland volume secondary to ischaemia and/or necrosis. Most cases occur in non-functioning pituitary adenoma but can also occur in functioning adenoma. Certain predisposing factors can result in PA and the use of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer (PCa) is one such condition. Once diagnosed, both surgical and conservative management has been used for the treatment of PA. We present a case of a man in his late 50s who developed PA following treatment of PCa with leuprolide. His symptoms developed insidiously and he presented 6 months after symptom onset. Anterior pituitary hormone workup along with pituitary MRI confirmed the diagnosis of PA and patient was subsequently treated with adequate replacement of pituitary hormone with significant improvement in his symptoms …

Epidemiology and determinants of survival for primary intestinal non-Hodgkin lymphoma: a population-based study

Authors

Vinit Singh,Dhairya Gor,Varsha Gupta,Aasems Jacob,Doantrang Du,Hussam Eltoukhy,Trishala Meghal

Journal

World Journal of Oncology

Published Date

2022/8

BackgroundGastrointestinal tract is the most common site of extranodal non-Hodgkin lymphoma (EN-NHL). Most of the published data have been on gastric NHL with limited studies on primary intestinal non-Hodgkin lymphoma (PI-NHL) considering rare incidence. We performed epidemiological and survival analysis for PI-NHL from the Surveillance, Epidemiology, and End Results (SEER) 18 database.MethodsA total of 9,143 PI-NHL cases of age≥ 18 years were identified from the SEER 18 database for the period 2000-2015. Totally, 8,568 patients were included for survival analysis. Cause-specific survival (CSS) and overall survival (OS) analysis were done for PI-NHL and PI-diffuse large B-cell lymphoma (PI-DLBCL) using sex, age of onset, treatment, histology, stage, and year of diagnosis. Survival analysis was done by using Cox proportional hazard model and Kaplan-Meier plot with log-rank test.ResultsThe …

A Case of Undiagnosed Functional Gonadotroph Adenoma Leading to Ovarian Hyperstimulation Syndrome

Authors

Omkar Mayur,Ghada Elshimy,Rashika Bansal,Aasems Jacob,Rishi Raj

Journal

Cureus

Published Date

2022/6/23

A functional gonadotroph adenoma is a very rare endocrinopathy, and only a few cases have been reported in the literature. We present a case of a woman in her early 50s with a past medical history of recurrent ovarian cysts who developed bilateral hemianopsia and was referred to the endocrinology clinic after a magnetic resonance imaging (MRI) identified a pituitary mass. Anterior pituitary hormone workup confirmed hypersecretion of follicle-stimulating hormone (FSH), which suggested ovarian hyperstimulation syndrome (OHSS) as the etiology of recurrent ovarian cysts. The patient underwent transsphenoidal resection of the pituitary tumor with improvement in visual symptoms. Our case illustrates that functional gonadotroph adenoma can be a potential cause of OHSS apart from the setting of assisted reproductive technology and hence warranting a meticulous endocrine evaluation to rule out this rare disease.

Oxalate Nephropathy in a Patient with COVID-19-Infection: Causation or Association

Authors

Lakshmi Kannan,Rishi Raj,Sheharyar Abbasi,Aasems Jacob

Published Date

2022/2/21

The pandemic due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV2) has led to significant morbidity and mortality over the last two years. Although lungs are the primarily involved organ with infection due to COVID-19, there have been rising rates of COVID-19 related kidney disease. Kidney injury among patients with COVID-19 can present in multiple ways, and different pathophysiologic mechanisms have been suggested. We describe a case of an elderly woman who developed acute kidney injury secondary to oxalate nephropathy in the setting of severe COVID-19 infection and needed hemodialysis. Our case illustrates that calcium oxalate crystal deposition in the kidney (oxalate nephropathy) could be one of the possible pathophysiologic mechanisms of renal dysfunction in the setting of COVID-19.

Immune checkpoint inhibitors related endocrine adverse events

Authors

Ghada Elshimy,Rishi Raj,Halis Kaan Akturk,Aleksandra Schriber,Nuria Sisterna,Iram Ahmad,Aasems Jacob,Aaron W Michels,Ricardo Correa

Published Date

2022/2/8

Immune checkpoint inhibitors (ICIs) are currently used for the treatment of various types of cancers. Despite the important clinical benefits, these medications can lead to a spectrum of side effects called immune-related adverse events (irAEs). Endocrine irAEs are among the most common irAEs that have been reported in clinical trials and post-marketing settings with an overall incidence of around 10% of patients treated with ICIs. These include hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, insulin‐deficient diabetes mellitus, hypogonadism, hypoparathyroidism, hypocalcemia, and other less commonly reported side effects. The symptoms can sometimes be nonspecific but life-threatening. Hence, physicians should be aware of the endocrine irAEs which can occur anytime during treatment or even after discontinuation of the medications. In this chapter, we will be discussing in detail the ICI-related endocrine irAEs and their management. In addition, we will be suggesting an algorithm to be used in the clinical setting for screening and monitoring of the endocrine iRAEs. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW. ENDOTEXT. ORG.

Acute Spinal Cord Ischemia Associated With Cocaine Use: A Case Report

Authors

Ramya Akella,Rishi Raj,Lakshmi Kannan,Aasems Jacob,Subramanya Shyam Ganti

Journal

Cureus

Published Date

2022/6/6

Cocaine is one of the most common causes of acute drug-related emergency department visits in the United States. It produces a dose-dependent increase in heart rate and blood pressure accompanied by increased arousal and a sense of self-confidence, euphoria, and well-being. Its use is typically followed by a craving for more of the drug. It can also lead to acute events such as myocardial infarction, seizures, and cerebrovascular events. Here, we present a case of cocaine-induced spinal cord ischemia resulting in quadriplegia. Our case highlights that, in a young patient presenting with acute non-traumatic myelopathy, it is important to consider cocaine use among other differentials.

Outcomes of Elderly Patients with Acute Lymphoblastic Leukemia: Trends of Survival in the Last Two Decades

Authors

Varsha Gupta,Vinit Singh,Aasems Jacob,Ravneet Bajwa,Michael J Levitt

Journal

Blood

Published Date

2022/11/15

Introduction: In the last few decades, there have been substantial improvements in outcomes of younger patients with Acute Lymphoblastic Leukemia (ALL). Unfortunately, similar results were not seen in the elderly population due to varied genetic makeup and lesser tolerance to aggressive pediatric-based treatment regimens. Lately, with developments, including novel therapeutics like Tyrosine Kinase Inhibitors (TKIs), Inotuzumab ozogamicin, Blinatumomab, CAR-T, significant improvements in survival have been noted. Our objective was to describe survival trends among elderly diagnosed with ALL in the last few years. We also described survival outcomes based on demographics and genetic features.Methods: We identified patients with ALL aged≥ 65 years from the Surveillance, Epidemiology and End Results (SEER) database for 2000-2018 period using WHO ICD-O-3 codes. Gender, age, race, histology …

External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy

Authors

Satya Das,Aman Chauhan,Liping Du,Katharine E Thomas,Aasems Jacob,Aimee Schad,Shikha Jain,Aaron Jessop,Chirayu Shah,David Eisner,Dana B Cardin,Kristen K Ciombor,Laura W Goff,Marques Bradshaw,Dominique Delbeke,Martin Sandler,Robert A Ramirez,Jordan Berlin

Journal

JAMA network open

Published Date

2022/1/4

ImportanceDespite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate benefit from the therapy for individual patients has been previously defined.ObjectiveTo assess whether the prognostic ability of the clinical score (CS) could be validated in an external cohort of patients with WD NETs.Design, Setting, and ParticipantsThis multicenter cohort study’s analysis included patients with WD NETs who were under consideration for peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-dotatate between March 1, 2016, and March 17, 2020. The original cohort included patients from Vanderbilt-Ingram Cancer Center. The validation cohort included patients from Ochsner Medical Center, Markey Cancer Center, and Rush Medical Center. Patients with paragangliomas, pheochromocytomas and …

An update on the management of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)

Authors

Aasems Jacob,Rishi Raj,Derek B Allison,Heloisa P Soares,Aman Chauhan

Published Date

2022/5

Opinion statementThe classification of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) is evolving, and no clear management guidelines are currently available. However, recent studies provide insight into factors affecting outcomes and could help develop treatment decisions for patients with these rare malignancies. The majority of MiNENs have a poorly differentiated neuroendocrine carcinoma (NEC) component which is associated with an aggressive clinical course and poor outcomes. Due to the paucity of clinical trials, strategies adopted in gastrointestinal cancers and NECs are used to manage MiNENs. It is also to be noted that the thoracic neuroendocrine neoplasm WHO 2021 classification does not recognize MiNEN terminology but suggests an equivalent terminology called “combined neuroendocrine non neuroendocrine neoplasm.” Surgical management is appropriate in early-stage …

Coexisting portal vein thrombosis and aortic thrombosis in a patient with COVID-19: a case report and literature review

Authors

Ramya Akella,Rishi Raj,Lakshmi Kannan,Aasems Jacob

Journal

IDCases

Published Date

2022/1/1

The Coronavirus Disease 2019 (COVID-19) pandemic has rapidly progressed, resulting in significant global morbidity and mortality. Predominantly affecting the respiratory tract, it has been found to be associated with extrapulmonary manifestations such as coagulopathies. We hereby report a case of an elderly man with no predisposing risk factors or history of hypercoagulable disorder who presented with acute onset abdominal pain and was diagnosed with portal vein thrombosis and splenic infarct two weeks following mild COVID-19. Incidentally, the patient was also noted to have aortic thrombosis. The patient was treated with therapeutic anticoagulation with complete resolution in his symptoms. Our case highlights a high risk of coagulopathy following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Case report: SARS-CoV-2 infection as a trigger for diabetic ketoacidosis and newly detected pancreatic autoantibodies

Authors

Rahul Mishra,Ghada Elshimy,Lakshmi Kannan,Aasems Jacob,Rishi Raj

Journal

Frontiers in Endocrinology

Published Date

2022/8/10

A 39-year-old-woman with a past medical history of type 2 diabetes mellitus (T2DM) on oral hypoglycemic agents presented to the emergency room with nausea, vomiting, shortness of breath, and altered mental status. Seven days prior to presentation, she was diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Laboratory workup on presentation confirmed the diagnosis of diabetic ketoacidosis (DKA) (blood glucose 523 mg/dl, beta-hydroxybutyrate 8.91 mmol/l, pH 6.9, bicarbonate 11 mEq/l, anion gap 25 mEq/l, and HbA1c 10.8%). She was managed for DKA with hydration and insulin drip and discharged home. However, to our surprise, at the 2-week follow-up visit, she was found to have positive antibodies for zinc transporter 8 (ZnT8) (samples were collected on day of presentation). The rest of her antibodies associated with T1DM were negative. She was therefore started on a basal-bolus regimen and managed as type 1 diabetes mellitus (T1DM). Our case illustrates that there is an increased risk of T1DM following infection with SARS-CoV-2.

Immobilization-induced hypercalcemia in COVID-19 with a prolonged Intensive Care Unit stay

Authors

Lakshmi Kannan,Rishi Raj,William Rhoad,Ramya Akella,Aasems Jacob,William D Rhoad

Journal

Cureus

Published Date

2022/4/12

Immobilization is an uncommon etiology of hypercalcemia. It is usually seen in conditions associated with limited movements such as spinal cord injuries, vascular events, or following prolonged hospitalization. Hereby, we present a case of a young patient who had prolonged hospitalization following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During her prolonged and complicated hospital stay, she developed severe hypercalcemia secondary to immobilization, which was resistant to treatment with hydration, calcitonin, and denosumab. One dose of zoledronic acid was used, although the patient was on hemodialysis, with adequate response in calcium levels. This case illustrates that patients with COVID-19-related hospitalization are at increased risk of immobilization-induced hypercalcemia, likely due to prolonged hospital stay due to critical illness and lack of early physical therapy during hospitalization.

Androgen receptor signaling in prostate cancer and therapeutic strategies

Authors

Aasems Jacob,Rishi Raj,Derek B Allison,Zin W Myint

Published Date

2021/10/28

Simple Summary Early-stage and castration-sensitive prostate cancer (PCa) growth is solely mediated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have significantly improved clinical outcomes among men with PCa. In the metastatic castration-resistant PCa, there is presence of both androgen-dependent and androgen-independent cells driving the tumor growth. Despite the use of ARSIs, disease progression ultimately occurs in all patients with PCa and is due to genetic alterations in ARs, resulting in the outgrowth of androgen-independent cells. The possible mechanisms include development of AR splice variants of which AR-V7 is more common, AR point mutations, and AR overexpression. In addition, restoration of downstream signaling through alternate pathways can also lead to androgen-independent growth of PCa. Therapeutic strategies to overcome these resistance mechanisms and establish predictive biomarkers are still in clinical trials. This review article details the current evidence on clinically relevant driver mechanisms, relevant biomarkers, and treatment modalities to overcome resistance. Abstract Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic strategies targeting androgen receptor (AR). These androgen-receptor signaling inhibitors (ARSI) include androgen synthesis inhibitor-abiraterone and androgen receptor antagonists-enzalutamide, apalutamide, and darolutamide. Although these medications provide significant improvement in survival among men with prostate cancer, drug resistance develops in nearly all …

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy …

Authors

Satya Das,Aman Chauhan,Liping Du,Katharine Thomas,Aasems Jacob,Aimee Schad,Shikha Jain,Aaron Jessop,Chirayu Shah,David Eisner,Dana Backlund Cardin,Kristen Keon Ciombor,Laura Williams Goff,Marques Bradshaw,Dominique Delbeke,Martin P Sandler,Jordan Berlin,Robert A Ramirez

Published Date

2021/5/20

4109Background: Questions remain regarding when to sequence PRRT and how to categorize pts being considered for the treatment (tx). We previously developed a CS (comprised of 5 categories: available non-PRRT tx for tumor type, prior systemic tx, pt symptoms, tumor burden in critical organs and peritoneal carcinomatosis presence) at Vanderbilt Ingram Cancer Center (VICC) for pts being considered for PRRT to help answer these questions and demonstrated the score to be associated with progression-free survival (PFS) in pts receiving PRRT. Herein, we present the performance of the CS in a validation cohort (VC) and combined cohort (CC). Methods: Our original cohort (OC) included pts with progressive WD NETs (N = 122) under consideration for PRRT between 3/1/2016-3/17/2020 at VICC while our VC included pts under consideration for PRRT (N = 126) between 1/25/2017-11/18/2019 at Ochsner …

How I Treat Neuroendocrine Tumors

Authors

Aasems Jacob,Gaby Gabriel,Robert A Ramirez,Yi-Zarn Wang,Lowell Anthony,Aman Chauhan

Journal

Indian Journal of Medical and Paediatric Oncology

Published Date

2021/10

Neuroendocrine tumors (NETs) originate from diffuse neuroendocrine cell system and can develop in many organs. Gastroenteropancreatic (GEP) NETs account for approximately 70%, followed by bronchopulmonary and thymic NETs. 1 The World Health Organization (WHO) classification divides GEP NETs into well-differentiated NETs and poorly differentiated neuroendocrine carcinoma (NEC). Welldifferentiated NETs can be grade 1 (G1; mitotic count< 2 per 10 HPF-high power field, Ki-67< 3%), G2 (mitotic count: 2–20, Ki-67: 3–20%) tumors, and G3 (mitotic count> 20, Ki-67> 20%). 2 Poorly differentiated NECs are always G3 tumors with> 20 mitotic count and Ki-67 index> 20% and include small-and large-cell NECs. 2 A total of 10 to 13% of NETs do not have a primary site identified at the time of diagnosis and are called NETs of unknown primary. 1, 3 NETs can also be differentiated based on the secretion of …

Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II …

Authors

Aasems Jacob,Alexander Kreimer,Jing Wei,Jianrong Wu,Lauren Corum,Ellen Reusch,Jerold Woodward,Donald Cohen,Subbarao Bondada,Val R Adams,Rachael Morgan,Ronald C McGarry,William H St Clair,Mahesh R Kudrimoti,Zin Myint,Susanne M Arnold,John L Villano

Published Date

2021/5/20

2628Background: Preclinical models demonstrate that combined RT with immune checkpoint inhibitor (ICI) results in specific CD8+ T-cell phenotype associated with a tumor-reactive population resulting in significant tumor response. Sequential treatment could allow radiation to release tumor antigens from immune inaccessible areas and provide robust anti-tumor immune response with ICI. We report an interim analysis of the phase II clinical trial evaluating the efficacy and safety of the combination. Methods: Advanced NSCLC and HNSCC patients who had initiated on FDA approved single-agent ICI were eligible. Patients were given SBRT (BED>100Gy) or 30 Gy fractionated RT delivered as a 3-dimensional dose to a single metastatic site within 14 days of the first ICI dose. Primary objective was 6-month PFS and secondary objectives were safety and tolerability, 1Y PFS and OS. This interim analysis was done …

See List of Professors in Aasems Jacob University(University of Kentucky)

Aasems Jacob FAQs

What is Aasems Jacob's h-index at University of Kentucky?

The h-index of Aasems Jacob has been 8 since 2020 and 8 in total.

What are Aasems Jacob's top articles?

The articles with the titles of

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib

A Tale of Two Hematological Malignancies: CML Followed by CLL in the Same Patient

Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs

AIMS65, Glasgow-Blatchford bleeding score and modified Glasgow-Blatchford bleeding score in predicting outcomes of upper gastrointestinal bleeding: An accuracy and calibration …

Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment

Epidemiology and determinants of survival for primary intestinal non-Hodgkin lymphoma: a population-based study

A Case of Undiagnosed Functional Gonadotroph Adenoma Leading to Ovarian Hyperstimulation Syndrome

Oxalate Nephropathy in a Patient with COVID-19-Infection: Causation or Association

...

are the top articles of Aasems Jacob at University of Kentucky.

What are Aasems Jacob's research interests?

The research interests of Aasems Jacob are: Oncology, Hematology, Healthcare disparities, Immunotherapy, Lung Cancer

What is Aasems Jacob's total number of citations?

Aasems Jacob has 238 citations in total.

What are the co-authors of Aasems Jacob?

The co-authors of Aasems Jacob are Jill Kolesar, Susanne Arnold, MD, Halis Kaan Akturk, Eric B. Durbin, DrPH, MS, Aman Chauhan, Derek Allison.

    Co-Authors

    H-index: 48
    Jill Kolesar

    Jill Kolesar

    University of Kentucky

    H-index: 38
    Susanne Arnold, MD

    Susanne Arnold, MD

    University of Kentucky

    H-index: 27
    Halis Kaan Akturk

    Halis Kaan Akturk

    University of Colorado Denver

    H-index: 21
    Eric B. Durbin, DrPH, MS

    Eric B. Durbin, DrPH, MS

    University of Kentucky

    H-index: 19
    Aman Chauhan

    Aman Chauhan

    University of Kentucky

    H-index: 17
    Derek Allison

    Derek Allison

    University of Kentucky

    academic-engine

    Useful Links